Patent ID: 8580303
Filing Date: 2013-11-12
Classification: A61K,A61P

Abstract:
1. An oral dosage form comprising gabapentin or a pharmaceutically acceptable salt thereof, wherein the dosage form comprises (a) at least one component that contains a gas generating agent and the gabapentin, and (b) at least one hydrophilic membrane in the form of a sachet, which contains component (a), and wherein the hydrophilic membrane expands by inflation, floats on the aqueous phase in the stomach, and is permeable to gastric juice, and wherein gabapentin is released from the dosage form into the upper gastrointestinal tract over about 5-12 hours at a rate sufficient to achieve a lower maximum plasma concentration than that provided by an immediate release dosage form comprising an equal amount of gabapentin, and bioavailability of gabapentin is at least 80% of that provided by the immediate release dosage form comprising an equal amount of gabapentin as measured by the area under the plasma concentration-time curve, AUC